A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Highlights Semaglutide medications like Ozempic may cause facial changes. You can take steps to help minimize or prevent ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...